AURORA, Ontario, Aug. 17 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. today announced the appointment of Kazimierz Roszkowski-Sliz, M.D., Ph.D., to its board of directors. Professor Roszkowski-Sliz is replacing Professor Slawomir Majewski, who has stepped down from the board to assume the advisory role of European medical director for Helix.
“Professor Roszkowski-Sliz is an excellent addition to our board of directors,” said Donald H. Segal, Ph.D., chairman and CEO of Helix BioPharma. “His expertise in lung disease, especially lung cancer, will be invaluable to Helix as we continue to drive our L-DOS47 non-small cell lung cancer program towards clinical development. We also want to thank Professor Majewski for his service on the board. We are fortunate that he will continue to provide us with guidance on our European clinical development activities.”
About Helix BioPharma Corp.
For further information contact:
Editor’s Note: Photograph is available on request
Helix BioPharma Corp.
